Amino acid ester prodrugs of the anticancer agent gemcitabine: Synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport

Xueqin Song, Philip L. Lorenzi, Christopher P. Landowski, Balvinder S. Vig, John M. Hilfinger, Gordon L. Amidon

Research output: Contribution to journalArticleScientificpeer-review

89 Citations (Scopus)

Abstract

Gemcitabine, a clinically effective nucleoside anticancer agent, is a polar drug with low membrane permeability and is administered intravenously. Further, extensive degradation of gemcitabine by cytidine deaminase to an inactive metabolite in the liver affects its activity adversely. Thus, strategies that provide both enhanced transport and high metabolic bioevasion would potentially lead to oral alternatives that may be clinically useful. The objective of this study was to evaluate whether amino acid ester prodrugs of gemcitabine would (a) facilitate transport across intestinal membranes or across cells that express hPEPT1 and (b) provide resistance to deamination by cytidine deaminase. 3′-Monoester, 5′-monoester, and 3′,5′-diester prodrugs of gemcitabine utilizing aliphatic (L-valine, D-valine, and L-isoleucine) and aromatic (L-phenylalanine and D-phenylalanine) amino acids as promoieties were synthesized and evaluated for their affinity and direct hPEPT1-mediated transport in HeLa/hPEPT1 cells. All prodrugs exhibited enhanced affinity (IC 50 : 0.14-0.16 mM) for the transporter. However, only the 5′-L-valyl and 5′-L-isoleucyl monoester prodrugs exhibited (a) increased uptake (11.25- and 5.64-fold, respectively) in Hel_a/hPEPT1 cells compared to HeLa cells and (b) chemical stability in buffers, that were comparable to valacyclovir, a commercially marketed oral amino acid ester prodrug. The widely disparate enzymatic bioconversion profiles of the 5′-L-valyl and 5′-L-isoleucyl prodrugs in Caco-2 cell homogenates along with their significant resistance to deamination by cytidine deaminase suggest that the disposition of gemcitabine following oral administration would be controlled by the rate of bioconversion following transport across the intestinal epithelial membrane. The combined results also suggest that it may be possible to modulate these characteristics by the choice of the amino acid promoiety.

Original languageEnglish
Pages (from-to)157-167
Number of pages11
JournalMolecular Pharmaceutics
Volume2
Issue number2
DOIs
Publication statusPublished - 1 Mar 2005
MoE publication typeA1 Journal article-refereed

Fingerprint

gemcitabine
Prodrugs
Antineoplastic Agents
Esters
Cytidine Deaminase
Amino Acids
Deamination
valacyclovir
Valine
Phenylalanine
HeLa Cells
Membranes
Caco-2 Cells
Isoleucine
Nucleosides
Oral Administration
Permeability
Buffers

Keywords

  • Amino acid esters
  • Cytidine deaminase
  • Gemcitabine
  • Peptide transporter
  • Prodrug

Cite this

Song, Xueqin ; Lorenzi, Philip L. ; Landowski, Christopher P. ; Vig, Balvinder S. ; Hilfinger, John M. ; Amidon, Gordon L. / Amino acid ester prodrugs of the anticancer agent gemcitabine : Synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. In: Molecular Pharmaceutics. 2005 ; Vol. 2, No. 2. pp. 157-167.
@article{dd0c7c6e8dbd4f618036e3fe9dcb716a,
title = "Amino acid ester prodrugs of the anticancer agent gemcitabine: Synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport",
abstract = "Gemcitabine, a clinically effective nucleoside anticancer agent, is a polar drug with low membrane permeability and is administered intravenously. Further, extensive degradation of gemcitabine by cytidine deaminase to an inactive metabolite in the liver affects its activity adversely. Thus, strategies that provide both enhanced transport and high metabolic bioevasion would potentially lead to oral alternatives that may be clinically useful. The objective of this study was to evaluate whether amino acid ester prodrugs of gemcitabine would (a) facilitate transport across intestinal membranes or across cells that express hPEPT1 and (b) provide resistance to deamination by cytidine deaminase. 3′-Monoester, 5′-monoester, and 3′,5′-diester prodrugs of gemcitabine utilizing aliphatic (L-valine, D-valine, and L-isoleucine) and aromatic (L-phenylalanine and D-phenylalanine) amino acids as promoieties were synthesized and evaluated for their affinity and direct hPEPT1-mediated transport in HeLa/hPEPT1 cells. All prodrugs exhibited enhanced affinity (IC 50 : 0.14-0.16 mM) for the transporter. However, only the 5′-L-valyl and 5′-L-isoleucyl monoester prodrugs exhibited (a) increased uptake (11.25- and 5.64-fold, respectively) in Hel_a/hPEPT1 cells compared to HeLa cells and (b) chemical stability in buffers, that were comparable to valacyclovir, a commercially marketed oral amino acid ester prodrug. The widely disparate enzymatic bioconversion profiles of the 5′-L-valyl and 5′-L-isoleucyl prodrugs in Caco-2 cell homogenates along with their significant resistance to deamination by cytidine deaminase suggest that the disposition of gemcitabine following oral administration would be controlled by the rate of bioconversion following transport across the intestinal epithelial membrane. The combined results also suggest that it may be possible to modulate these characteristics by the choice of the amino acid promoiety.",
keywords = "Amino acid esters, Cytidine deaminase, Gemcitabine, Peptide transporter, Prodrug",
author = "Xueqin Song and Lorenzi, {Philip L.} and Landowski, {Christopher P.} and Vig, {Balvinder S.} and Hilfinger, {John M.} and Amidon, {Gordon L.}",
year = "2005",
month = "3",
day = "1",
doi = "10.1021/mp049888e",
language = "English",
volume = "2",
pages = "157--167",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society ACS",
number = "2",

}

Amino acid ester prodrugs of the anticancer agent gemcitabine : Synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. / Song, Xueqin; Lorenzi, Philip L.; Landowski, Christopher P.; Vig, Balvinder S.; Hilfinger, John M.; Amidon, Gordon L.

In: Molecular Pharmaceutics, Vol. 2, No. 2, 01.03.2005, p. 157-167.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Amino acid ester prodrugs of the anticancer agent gemcitabine

T2 - Synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport

AU - Song, Xueqin

AU - Lorenzi, Philip L.

AU - Landowski, Christopher P.

AU - Vig, Balvinder S.

AU - Hilfinger, John M.

AU - Amidon, Gordon L.

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Gemcitabine, a clinically effective nucleoside anticancer agent, is a polar drug with low membrane permeability and is administered intravenously. Further, extensive degradation of gemcitabine by cytidine deaminase to an inactive metabolite in the liver affects its activity adversely. Thus, strategies that provide both enhanced transport and high metabolic bioevasion would potentially lead to oral alternatives that may be clinically useful. The objective of this study was to evaluate whether amino acid ester prodrugs of gemcitabine would (a) facilitate transport across intestinal membranes or across cells that express hPEPT1 and (b) provide resistance to deamination by cytidine deaminase. 3′-Monoester, 5′-monoester, and 3′,5′-diester prodrugs of gemcitabine utilizing aliphatic (L-valine, D-valine, and L-isoleucine) and aromatic (L-phenylalanine and D-phenylalanine) amino acids as promoieties were synthesized and evaluated for their affinity and direct hPEPT1-mediated transport in HeLa/hPEPT1 cells. All prodrugs exhibited enhanced affinity (IC 50 : 0.14-0.16 mM) for the transporter. However, only the 5′-L-valyl and 5′-L-isoleucyl monoester prodrugs exhibited (a) increased uptake (11.25- and 5.64-fold, respectively) in Hel_a/hPEPT1 cells compared to HeLa cells and (b) chemical stability in buffers, that were comparable to valacyclovir, a commercially marketed oral amino acid ester prodrug. The widely disparate enzymatic bioconversion profiles of the 5′-L-valyl and 5′-L-isoleucyl prodrugs in Caco-2 cell homogenates along with their significant resistance to deamination by cytidine deaminase suggest that the disposition of gemcitabine following oral administration would be controlled by the rate of bioconversion following transport across the intestinal epithelial membrane. The combined results also suggest that it may be possible to modulate these characteristics by the choice of the amino acid promoiety.

AB - Gemcitabine, a clinically effective nucleoside anticancer agent, is a polar drug with low membrane permeability and is administered intravenously. Further, extensive degradation of gemcitabine by cytidine deaminase to an inactive metabolite in the liver affects its activity adversely. Thus, strategies that provide both enhanced transport and high metabolic bioevasion would potentially lead to oral alternatives that may be clinically useful. The objective of this study was to evaluate whether amino acid ester prodrugs of gemcitabine would (a) facilitate transport across intestinal membranes or across cells that express hPEPT1 and (b) provide resistance to deamination by cytidine deaminase. 3′-Monoester, 5′-monoester, and 3′,5′-diester prodrugs of gemcitabine utilizing aliphatic (L-valine, D-valine, and L-isoleucine) and aromatic (L-phenylalanine and D-phenylalanine) amino acids as promoieties were synthesized and evaluated for their affinity and direct hPEPT1-mediated transport in HeLa/hPEPT1 cells. All prodrugs exhibited enhanced affinity (IC 50 : 0.14-0.16 mM) for the transporter. However, only the 5′-L-valyl and 5′-L-isoleucyl monoester prodrugs exhibited (a) increased uptake (11.25- and 5.64-fold, respectively) in Hel_a/hPEPT1 cells compared to HeLa cells and (b) chemical stability in buffers, that were comparable to valacyclovir, a commercially marketed oral amino acid ester prodrug. The widely disparate enzymatic bioconversion profiles of the 5′-L-valyl and 5′-L-isoleucyl prodrugs in Caco-2 cell homogenates along with their significant resistance to deamination by cytidine deaminase suggest that the disposition of gemcitabine following oral administration would be controlled by the rate of bioconversion following transport across the intestinal epithelial membrane. The combined results also suggest that it may be possible to modulate these characteristics by the choice of the amino acid promoiety.

KW - Amino acid esters

KW - Cytidine deaminase

KW - Gemcitabine

KW - Peptide transporter

KW - Prodrug

UR - http://www.scopus.com/inward/record.url?scp=23844467048&partnerID=8YFLogxK

U2 - 10.1021/mp049888e

DO - 10.1021/mp049888e

M3 - Article

C2 - 15804190

AN - SCOPUS:23844467048

VL - 2

SP - 157

EP - 167

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 2

ER -